Recent Advances in Antiviral Therapy for Chronic Hepatitis C

Table 1

Profile of NS3/4A protease inhibitors.

Generation			Active against HCV genotype	Genetic barriers	Resistant association variants
1st, 1st-wave	VX-950	Telaprevir	1a/1b, 2	Low	V36A/M		R155K/T/Q	A156S/D/T/V
1st, 1st-wave		Boceprevir	1a/1b, 2	Low	V36A/M		R155K/T/Q	A156S/D/T/V
1st, 2nd-wave	BI 201335	Faldaprevir	1a/1b, 2	Moderate			R155K/T/Q		D168A/V/T/H	V170A/T
1st, 2nd-wave	TMC-435	Simeprevir	1, 2, and 4–6	Moderate		Q80R/K			D168A/V/T/H
1st, 2nd-wave	MK-7009	Vaniprevir	1a/1b	Moderate			R155K/T/Q	A156S/D/T/V	D168A/V/T/H
1st, 2nd-wave	BMS-650032	Asunaprevir	1, 4	Moderate		Q80R/K	R155K/T/Q		D168A/V/T/H
1st, 2nd-wave	ABT-450	Paritaprevir	1	Moderate			R155K/T/Q		D168A/V/T/H
2nd	GS-9857		1–4				R155K/T/Q	A156S/D/T/V	D168A/V/T/H
2nd	ACH-1625	Sovaprevir
2nd	MK-5172	Grazoprevir	1a/1b, 2, and 4–6	High			R155K/T/Q	A156S/D/T/V	D168A/V/T/H

Reference [16] Vermehren and Sarrazin 2012.